Immuno-Oncology | Specialty

Dr. Balar Discusses Study of Immunotherapy Combination in Bladder Cancer

September 6th 2018

Arjun V. Balar, MD, assistant professor, Department of Medicine, director, Genitourinary Medical Oncology Program, NYU Langone’s Perlmutter Cancer Center, discusses a study of an immunotherapy combination in bladder cancer.

FDA Delays Decision on Frontline Atezolizumab for NSCLC

September 6th 2018

The FDA has extended the review period for a supplemental biologics license application for atezolizumab for use in combination with bevacizumab, carboplatin, and paclitaxel for the first-line treatment of patients with metastatic nonsquamous non–small cell lung cancer.

Dr. Sznol Discusses Immunotherapy in Non-Clear Cell Renal Cancer

September 6th 2018

Mario Sznol, MD, professor of medicine, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses immunotherapy in non-clear cell renal cancer.

Evidence Builds for Tumor Mutational Burden as Immunotherapy Biomarker

September 5th 2018

Amid a pressing need to identify patients most likely to respond to immune checkpoint inhibitors, tumor mutational burden has emerged as a highly promising and clinically validated biomarker.

Dr. Agarwala on Entinostat for Patients with Melanoma Who Progress on PD-1/PD-L1 Blockade

September 4th 2018

Sanjiv S. Agarwala, MD, chief of medical oncology and hematology, St. Luke’s Cancer Center, professor of medicine, Temple University School of Medicine, discusses the impact of entinostat for patients with melanoma who progress on a PD-1/PD-L1 blocking antibody.

NSCLC Findings Support Upfront Immunotherapy

September 2nd 2018

In the setting of advanced non–small cell lung cancer, the choice of up-front immunotherapy or chemotherapy, or combinations of both, is aided by findings from several trials.

Dr. Reardon on Efficacy/Safety of Immunotherapy Combination in Glioblastoma

August 31st 2018

David A. Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, discusses the safety and efficacy data of an immunotherapy combination in glioblastoma.

Dr. Naidoo on Treating Immune-Related Adverse Events in NSCLC

August 31st 2018

Jarushka Naidoo, MBBCh, assistant professor of oncology, Johns Hopkins University, discusses the treatment of patients with non–small cell lung cancer who develop immune-related adverse events (irAEs).

Optimizing Checkpoint Inhibitors Requires Careful AE Management

August 31st 2018

Jarushka Naidoo, MBBCh, discusses the toxicities associated with the use of immunotherapy in oncology, optimal methods of managing them, and the growing body of knowledge on why they occur.

Bunn Discusses Future of Immunotherapy in SCLC

August 30th 2018

Paul A. Bunn Jr, MD, discusses the potential for new agents to treat small cell lung cancer, the challenges involved in treating this population, and the ongoing search for biomarkers to guide treatment decisions.

Brahmer Highlights Immunotherapy Breakthroughs in Metastatic NSCLC

August 30th 2018

Julie R. Brahmer, MD, provides an overview of the landscape of metastatic non–small cell lung cancer, specifically addressing the combination immunotherapy studies with the greatest impact.

Dr. Munshi on the Role of Checkpoint Inhibitors in Myeloma

August 29th 2018

Nikhil C. Munshi, MD, director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, professor of medicine, Harvard Medical School, discusses the role of checkpoint inhibitors in myeloma.

Camidge Captures Complexities of Immunotherapy in NSCLC

August 28th 2018

D. Ross Camidge, MD, PhD, discusses the use of immunotherapy in patients with non–small cell lung cancer.

Expert Explains Successes, Challenges in Stage III Lung Cancer

August 28th 2018

Dustin M. Walters, MD, provides perspective on the treatment landscape of stage III non–small cell lung cancer.

Dr. Herbst Discusses Challenges With Immunotherapy in NSCLC

August 27th 2018

Roy S. Herbst, MD, PhD, Ensign Professor of Medicine and professor of pharmacology, chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital, discusses challenges with immunotherapy in non–small cell lung cancer.

Dr. Feliciano on Nivolumab in Small Cell Lung Cancer

August 27th 2018

Josephine Louella Feliciano, MD, assistant professor of oncology, Johns Hopkins Medicine, discusses the use of nivolumab (Opdivo) in patients with small cell lung cancer (SCLC).

Dr. Naidoo on Managing Immune-Related Adverse Events in NSCLC

August 24th 2018

Jarushka Naidoo, MBBCh, assistant professor of oncology, Johns Hopkins University, discusses managing immune-related adverse events (irAEs) in patients with non–small cell lung cancer (NSCLC).

Dr. Levy on Biomarkers of Response to Immunotherapy

August 24th 2018

Benjamin P. Levy, MD, assistant professor of oncology, clinical director of medical oncology, Johns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins Medicine, discusses biomarkers of response to immunotherapy.

Dr. Formenti on the Role of the Immune System in Cancer Treatment

August 24th 2018

Silvia Chiara Formenti, MD, chair, Department of Radiation Oncology, Weill Cornell, associate director, Meyer Cancer Center, radiation oncologist-in-chief, NewYork-Presbyterian Hospital, discusses the role of the immune system in cancer treatment.

Expert Highlights Promising Multiple Myeloma Data

August 24th 2018

Noopur Raje, MD, discusses the latest treatment advances in multiple myeloma.